Author:
Lisitsa Alexander V.,Averyanov Alexander V.,Sodaeva Svetlana K.,Klimanov Igor A.,Mikhailov Sergey E.
Abstract
The prospective single-blind randomized placebo-controlled study was performed.
The aim of the study was to investigate the effectiveness and safety of phospholipids' particles inhalation in patients with bronchial asthma. The results obtained demonstrate the statistically significant improvements both in clinical status and lung function tests. No any clinically significant adverse events were registered.
Reference14 articles.
1. Global Initiative for Asthma, National Institute of Health, National Heart Lung and Blood Institute, NHLBI/WHO Workshop report. Global strategy for asthma management and prevention. NHLBI/WHO workshop report 02-3659. January 1995, revised 2010.
2. Fireman P., Prenner B., Vincken W. et al. Longterm safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol Ann Allergy Asthma Immunol 2001; 86(5): 557-65.
3. Suissa S., Ernst R., Benayoun S. et al. Low-dose inhaled corticosteroids and the prevention of death from asthma N Engl J Med 2000; 343(5); 332-336.
4. Pauwels R.A., Löfdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997; 337(20): 1405-1411.
5. Fardon T.C., Burns P., Barnes M.L., Lipworth B.J. et al. A comparison of 2 extrafine hydrofluoroalkane- 134a-beclomethasone formulations on methacholine hyperresponsiveness. Ann Allergy Asthma Immunol. 2006; 96(3): 422-430.